Lyme VlsE Assay for Enhanced Borrelia Strain Detection

We are thrilled to announce the launch of our new Lyme VlsE Assay, a cutting-edge diagnostic tool powered by our proprietary Epitogen® technology. This breakthrough assay marks a significant advancement in the fight against Lyme disease by enabling both strain-level identification and enhanced diagnostic sensitivity.

Using Epitogen®, we have successfully expressed 27 full-length VlsE variants from clinically relevant Borrelia species, including: B. burgdorferi sensu stricto, B. afzelii, B. garinii, B. mayonii, B. spielmanii, B. bissetiae, B. bavariensis, B. valaisiana

This comprehensive antigen panel allows for deeper serological insights across the spectrum of Lyme-causing pathogens.

🔬 Intended Use

The Lyme VlsE Assay is designed for deployment in two key diagnostic scenarios:

1. Strain Identification in Confirmed Lyme Disease Cases
For patients with confirmed Lyme disease, the assay provides critical information about the specific Borrelia strain involved. This supports epidemiological tracking, inform treatment decisions, and enhance our understanding of regional strain prevalence.

2. Re-evaluation of Serology-Negative but Clinically Suspected Cases
In instances where patients exhibit symptoms consistent with Lyme disease but test negative in standard serological assays, the Lyme VlsE Assay offers an additional layer of diagnostic sensitivity.  Identification of less commonly targeted Borrelia species or variants, potentially improves diagnostic sensitivity and supporting earlier intervention.

 

For more information, please visit our Lyme product page.

For enquiries and orders, please email us at info@epitogenx.com.